歐洲藥品局（EMA）于2017年10月發(fā)布了番瀉葉和果的評(píng)估報(bào)告及其草藥專論修訂草案。介紹這3個(gè)文件的核心內(nèi)容，包括因長(zhǎng)期濫用的不良反應(yīng)以及潛在的遺傳毒性和致癌性，偶發(fā)便秘用藥持續(xù)時(shí)間不得超過1周，禁用于妊娠和哺乳期以及12歲以下兒童，以期對(duì)我國(guó)番瀉葉及其制劑的臨床合理使用及有效監(jiān)管有所裨益。

EMA issued the revised draft assessment report and herb on senna folium and senna fructus in October 2017. This paper introduced its core content, including medication duration of not more than 1 week in occasional constipation, contraindications for pregnancy and lactation as well as children under 12 years old, because of adverse reactions due to long-term abuse and potential genotoxicity and carcinogenicity. Look forward to benefit the clinical rational use and supervision of Sennae Folium and its preparations in China.